The latest update is out from BeiGene Ltd ( (HK:6160) ).
BeiGene, Ltd. has announced the composition of its board of directors, which includes a mix of executive, non-executive, and independent directors. The board oversees various committees such as Audit, Compensation, Nominating and Corporate Governance, Scientific Advisory, and Commercial and Medical Affairs Advisory, reflecting the company’s commitment to robust corporate governance and strategic oversight.
More about BeiGene Ltd
BeiGene, Ltd. is a biotechnology company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative cancer therapies. The company operates in the pharmaceutical industry, providing a range of oncology products and services to address unmet medical needs globally.
YTD Price Performance: 52.66%
Average Trading Volume: 2,473,919
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$241.4B
For an in-depth examination of 6160 stock, go to TipRanks’ Stock Analysis page.